Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • CTL109

    - PMLiVE

    Preparing for ASH 2025: Pharma’s role in hematology innovation

    As the global hematology community prepares for the 67th ASH® Annual Meeting and Exposition, Inizio experts share their perspectives on what’s driving the field forward – and how pharma companies...

    Inizio

    - PMLiVE

    J&J presents positive phase 3 results for Darzalex Faspro in smouldering multiple myeloma

    The early precursor of active disease accounts for 15% of all newly-diagnosed multiple myeloma cases

    - PMLiVE

    Roche announces five-year results for Polivy combination in diffuse large B-cell lymphoma

    Approximately 160,000 cases of the aggressive blood cancer are diagnosed globally every year

    - PMLiVE

    Sanofi’s rilzabrutinib shows promise in phase 3 immune thrombocytopenia study

    Approximately 9.5 per 100,000 people in the US are affected by the rare autoimmune disorder

    regeneron headquarters

    Regeneron shares positive late-stage results for poze-cemdi in rare blood disorder PNH

    Paroxysmal nocturnal haemoglobinuria affects up to 1.5 people per million in the US

    - PMLiVE

    Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting

    The company will present 90 abstracts from across a wide range of haematologic diseases, including results from three pivotal studies in lymphoma and haemophilia

    - PMLiVE

    NICE recommends Novartis’ Rydapt for advanced SM treatment

    The twice-daily, oral drug improves overall survival of people with the rare blood disorder

    - PMLiVE

    Roche, AbbVie hit by clinical hold for Venclexta in myeloma

    Safety concerns could hit blockbuster expectations

    Roche - Basel

    Roche files Venclexta plus Gazyva in CLL

    Chemo-free combo assessed via FDA's Real-Time review

    - PMLiVE

    AbbVie, Roche get FDA OK for broader use of Venclexta

    The drug is tipped to become a $2.5bn product by 2024

    - PMLiVE

    Roche’s MabThera ends drug drought for serious skin disease

    As biosimilars seize market share, Roche finds ways to extend blockbuster's revenues

    Roche Basel Switzerland

    Ocrevus helps Roche stave off biosimilar threat

    Its low price strategy for the CD20-targeting antibody is paying off

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links